CompletedPhase 4

The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant

Indonesia120 participantsStarted 2021-06-08

Plain-language summary

This study was to see the effectiveness of azithromycin in preventing the incidence of bronchopulmonary dysphasia in extremely preterm and very premature infants. Inclusion criteria were infants with a gestational age of 25-31 weeks 6 days who experienced respiratory distress and their families had agreed to participate in the study, then randomized. The intervention was in the form of giving azithromycin in the intervention group and no intervention was carried out in the control group and then followed up to 36 weeks PMA

Who can participate

Age range25 Weeks – 32 Weeks

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * premature infant 25-31 weeks 6 days with respiratory distress, Exclusion Criteria: * multiple congenital anomaly

What they're measuring

Bronchopulmonaty Dysplasia

Timeframe: BPD mild room air until 36 weeks PMA, BPD moderate use of oxygen <30% until 36 weeks PMA, BPD severe use of oxygen >30% until 36 weeks PMA

Trial details

NCT IDNCT05311228

SponsorIndonesia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-01

View on ClinicalTrials.gov More Bronchopulmonary Dysplasia trials